Geron (NASDAQ:GERN) Receives Neutral Rating from HC Wainwright

Geron (NASDAQ:GERN)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports.

Several other research firms have also weighed in on GERN. B. Riley lowered Geron from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. Barclays restated an “overweight” rating and issued a $4.00 target price (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. Stifel Nicolaus decreased their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and issued a $5.00 target price on shares of Geron in a research note on Wednesday. Finally, Scotiabank dropped their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Geron has a consensus rating of “Moderate Buy” and an average price target of $5.68.

Geron Stock Down 0.6 %

GERN stock opened at $1.60 on Wednesday. Geron has a 1-year low of $1.46 and a 1-year high of $5.34. The firm has a market capitalization of $1.02 billion, a PE ratio of -5.00 and a beta of 0.53. The business’s 50 day simple moving average is $2.73 and its 200 day simple moving average is $3.65. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The business had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. As a group, research analysts anticipate that Geron will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently modified their holdings of the stock. Alternative Investment Advisors LLC. raised its holdings in shares of Geron by 13.3% during the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 2,612 shares in the last quarter. Rovin Capital UT ADV increased its holdings in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,660 shares in the last quarter. Xponance Inc. boosted its holdings in Geron by 12.9% in the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 4,829 shares during the last quarter. US Bancorp DE grew its stake in shares of Geron by 68.4% during the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 7,429 shares during the period. Finally, KBC Group NV raised its holdings in Geron by 45.1% in the 4th quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 7,592 shares during the period. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.